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OBJECTIVE — The purpose of this study was to compare prevalence and risk factors for
diabetic retinopathy among U.K. residents of South Asian or white European ethnicity.
RESEARCHDESIGNANDMETHODS — Thiswasacommunity-basedcross-sectional
study involving 10 general practices; 1,035 patients with type 2 diabetes were studied: 421 of
South Asian and 614 of white European ethnicity. Diabetic retinopathy, sight-threatening reti-
nopathy,maculopathy,andpreviouslaserphotocoagulationtherapywereassessedaftergrading
ofretinalphotographs.Datawerecollectedonriskfactorsincludingage,duration,andtreatment
of diabetes, blood pressures, serum total cholesterol, and A1C.
RESULTS — Patients of South Asian ethnicity had signiﬁcantly higher systolic (144 vs.
137 mmHg, P  0.0001) and diastolic (84 vs. 74 mmHg, P  0.0001) blood pressure, A1C
(7.9 vs. 7.5%, P  0.0001), and total cholesterol (4.5 vs. 4.2 mmol/l, P  0.0001). Diabetic
retinopathy was detected in 414 (40%) patients (189 South Asian [45%] versus 225 white
European [37%]; P  0.0078). Sight-threatening retinopathy was detected in 142 (14%)
patients (68 South Asian [16%] versus 74 white European [12%]; P  0.0597). After
adjustment for confounders, there were signiﬁcantly elevated risks of any retinopathy and
maculopathy for South Asian versus white European patients.
CONCLUSIONS — Patients of South Asian ethnicity had a signiﬁcantly higher preva-
lence of diabetic retinopathy and maculopathy, with signiﬁcantly elevated systolic and
diastolic blood pressure, A1C, and total cholesterol; lower attained age; and younger age at
diagnosis. Earlier onset of disease and higher levels of modiﬁable risk factors make early
detection of diabetes, annual referral for retinal screening, and intensive risk factor control
key elements in addressing this health inequality.
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D
iabetes is one of the most common
chronic conditions in the Western
world,anditsprevalenceisincreas-
ing worldwide (1). Common risk factors
for the development of its microvascular
andmacrovascularcomplicationsinclude
duration of diabetes, poor glycemic con-
trol, elevated blood pressure, and dyslip-
idemia, the latter three of which are
potentially amenable to therapeutic inter-
vention (2,3). Diabetic retinopathy is the
leading cause of blindness among the
working age-group, the incidence of
blindness is increasing rapidly, and the
prevalence of visual impairment is higher
in South Asians in the U.K. (4,5). There is
conﬂicting evidence regarding the epide-
miology of diabetic retinopathy in South
Asians (6–9).
The U.K. Prospective Diabetes Study
(UKPDS) showed similar prevalences of
retinopathy at diagnosis and trial entry in
its South Asian, Afro-Caribbean, and
white European groups (10), whereas
Matheretal.(6)showedthatSouthAsians
were 1.5 times more likely to have laser
treatmentfordiabeticretinopathy.Recent
studiesintheU.K.reportedhigherpreva-
lences of retinopathy in South Asians
(7,8).
The aim of this study was to evaluate
the prevalence of diabetic retinopathy
and its risk factors among South Asians
compared with white Europeans in a
communitysettingintheU.K.,usingdata
from the Coventry Diabetes Retinopathy
Screeningserviceandgeneralpractitioner
records.
RESEARCH DESIGN AND
METHODS— In brief, the U.K. Asian
Diabetes Study (UKADS) was a cluster
randomized controlled trial designed to
evaluate the beneﬁts of an enhanced dia-
betes care package for people of South
Asian ethnicity with type 2 diabetes in
Coventry and Birmingham, U.K. (11,12).
The current study was a substudy of
UKADS, comprising a cross-sectional
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general practices in the Foleshill area of
CoventryincentralEngland.Retinalpho-
tographs and demographic data were col-
lectedfromtheCoventryandWarwickshire
Diabetes Retinal Screening Centre (CW-
DRSC) for UKADS patients, all of South
Asianethnicity,plusacomparisongroupof
whiteEuropeanpatientsfromthesamegeo-
graphical area of Coventry. Digital retinal
photographs(2eyes2ﬁelds),takenusing
a 3072  2906 Canon D20 back on a
Canon DGI nonmydriatic camera at 45°,
wereexaminedindependentlybytwoqual-
iﬁed retinal photography graders following
qualityassuranceprotocols.Aconﬁrmatory
grading by ophthalmologists for all ﬁlms
with changes greater than R1 (background
retinopathy) was undertaken, and a re-
search ophthalmologist (K.B.) undertook a
quality assurance check of 10% of photo-
graphs,followingauditspeciﬁcationsofthe
national screening guidelines. As a result of
this process, no instances of discordance in
grade were identiﬁed.
The grading of diabetic retinopathy
was based on the U.K.’s National Screen-
ing Committee guidelines, and retinopa-
thy was classiﬁed as none (R0), back-
ground (R1), preproliferative (R2), and
proliferative (R3), with or without macu-
lopathy (M) or previous photocoagula-
tion (P) (13). Final grading was based on
the worst eye, with any grade of dia-
betic retinopathy more severe than R1
(i.e., R2, R3, M, or P) classiﬁed as sight-
threatening retinopathy (STR). CWDRSC
has an overall ungradable rate of 2.4% of
photographs; patients with ungradable
photographs were excluded.
Clinical data were collected for all pa-
tients from their general practice records;
for UKADS patients, annual review data
collected at research clinics were used.
Details on risk factors including blood
pressure, duration of diabetes, age of on-
set of diabetes, A1C, serum creatinine,
and cholesterol were recorded. For
Foleshill general practitioners, biochemi-
cal measurement processing is all under-
takenbyacentrallaboratoryservicebased
in University Hospital Coventry and
Warwickshire.
Prevalence of any retinopathy, STR,
maculopathy, and previous photocoagu-
lationwasestimatedoverallandforSouth
Asian versus white European patients.
Age- and sex-standardized prevalence
and 95% CIs were estimated for any reti-
nopathy and STR plus maculopathy. De-
mographic and risk factors distributions
were compared between the groups, us-
ing the 
2 test, t test, and Mann-Whitney
U test as appropriate.
Multiple logistic regression was used
toestimatecrudeandadjustedoddsratios
(ORs) (95% CIs) to allow for differences
between groups with respect to demo-
graphic and risk factors and control for
potentially confounding variables. P 
0.05wasconsideredtobestatisticallysig-
niﬁcant. In developing logistic models,
the strategy was to ﬁt the simplest models
that adequately ﬁt the data to adjust for
potential confounding. Interaction effects
wereinvestigatedandexcludedwherenot
statistically signiﬁcant. Terms for sex, age
at diagnosis, and duration of diabetes
were included in all models, irrespective
of statistical signiﬁcance. For an expected
difference of 8–10% in retinopathy prev-
alence, with 80% power and P  0.05, it
was estimated that 900–1,000 patients
were needed.
RESULTS— A total of 1,079 patients
with gradable photographs were identi-
ﬁed, including 430 (40%) of South Asian
and649(60%)whiteEuropeanethnicity.
Of these, 44 patients were excluded as
having probable type 1 diabetes on the
basis of age of onset 30 years and the
need for insulin treatment at or near diag-
nosis. Of 1,035 patients remaining, there
were 421 (41%) of South Asian and 614
(59%) of white European ethnicity, in-
cluding 53% male and 47% female pa-
tients, with no difference in proportions
comparing ethnicity-deﬁned subgroups
(Table 1). More white European than
South Asian patients received insulin
treatment, but the difference was not sta-
tistically signiﬁcant (Table 1).
A total of 414 (40%) patients had di-
abetic retinopathy, with signiﬁcantly
more South Asian than white European
patients (Table 1). STR was detected in
142(14%)patients,withmoreSTRinthe
South Asian group and a difference of
borderline statistical signiﬁcance (Table
1). Maculopathy was detected in 105
(10%) patients, with a signiﬁcant differ-
ence between groups: 55 South Asian
(13%) versus 60 white European (9%)
patients (Table 1). Age- and sex-stan-
dardized prevalences showed a signiﬁcant
difference for any retinopathy (South
Asian 48.3% [95% CI 43.5–53.1] versus
white European 37.2% [33.3–41.0]) but
not STR (South Asian 17.3% [13.7–20.9]
versus white European 12.4% [9.7–15.0]
and were of borderline signiﬁcance for
maculopathy (South Asian 14.4% [11.1–
17.8] versus white European 8.8% [6.5–
11.1]). A total of 43 patients, 15 (4%)
SouthAsianand28(5%)whiteEuropean,
had previously had laser photocoagula-
tion therapy, with no signiﬁcant differ-
ence between the groups (Table 1).
Clinical data were collected and ana-
lyzed for 421 South Asian and 465 white
European patients. Patients of South Asian
ethnicity were signiﬁcantly younger, were
younger at diagnosis of diabetes, and had
shorter duration of diabetes (Table 2).
There were signiﬁcant differences with re-
spect to cardiovascular risk proﬁles: the
South Asian group had higher systolic and
diastolic blood pressures, A1C, and total
cholesterol, indicating considerably higher
overall cardiovascular risk (Table 2).
Levels of mean systolic blood pres-
sure and A1C were elevated in patients
withanyretinopathyandfurtherraisedin
those with STR, whereas similar increas-
ing patterns were apparent for both
ethnicity-deﬁned groups. The South
Asians had signiﬁcantly raised systolic BP
Table 1—Characteristics of patients with type 2 diabetes by ethnicity group
South
Asian
White
European Total P
n 421 614 1,035
Sex
Female 190 (45) 289 (48) 479 (47) 0.3386
Male 231 (55) 311 (52) 542 (53)
Treatment:
Insulin 71 (17) 127 (21) 198 (20) 0.1249
Tablets/diet 350 (83) 487 (79) 817 (80)
Any retinopathy (yes) 189 (45) 225 (37) 414 (40) 0.0078
STR (yes) 68 (16) 74 (12) 142 (14) 0.0597
Maculopathy (yes) 53 (13) 52 (8) 105 (10) 0.0310
Previous photocoagulation (yes) 15 (4) 28 (5) 43 (4) 0.4296
Data are n (%). n  1,035. Data are missing regarding the sex of 14 individuals.
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inopathyorbackgroundretinopathyonly
was present (Fig. 1A and B).
Treatment with insulin was signiﬁ-
cantly associated with higher prevalences
of any retinopathy, STR, maculopathy,
and previous photocoagulation (all with
P  0.0001). In unadjusted logistic re-
gression models, the South Asians had a
nonsigniﬁcantly elevated OR (95% CI)
for any retinopathy of 1.30 (0.99–1.71)
and STR of 1.38 (0.95–2.02) with macu-
lopathy of borderline signiﬁcance of 1.54
(1.00–2.38)(Table3).Inmodelsforboth
any retinopathy and maculopathy, a sta-
tistically signiﬁcant interaction effect for
ethnicity  duration was identiﬁed, im-
plying that the ethnicity effect varied de-
pending on diabetes duration. ORs (95%
CIs) for South Asian versus white Euro-
pean, adjusted for potential confounders,
for increasing duration of diabetes were
estimated: any retinopathy 2.40 (1.37–
4.22), 2.06 (1.22–2.56), and 1.77 (0.93–
1.83), and maculopathy 3.44 (1.50–
7.89), 2.86 (1.28–4.40), and 2.38
(1.00–2.71) for durations of 0, 5, and 10
years, respectively. In STR models, the ef-
fect of ethnicity was not statistically
signiﬁcant.
CONCLUSIONS — This primary
care–based study shows that U.K. resident
South Asians with diabetes have a signiﬁ-
cantly higher prevalence of any retinopathy
and maculopathy than indigenous white
Europeans. As reported previously, the
South Asian group in this study was
younger at diagnosis and had a shorter du-
ration of diabetes (14). Signiﬁcantly higher
systolic and diastolic blood pressures, A1C,
and cholesterol levels—all risk factors po-
tentially amenable to treatment—were ob-
served compared with those for the white
Europeangroup.Afteradjustmentforthese
differences, the excess risk of both any reti-
nopathy and maculopathy for the South
Asian group remained signiﬁcantly ele-
vated,suggestingfurtherriskattributableto
ethnicity. The risk of STR was raised for
South Asians but not statistically signiﬁ-
cantly so, perhaps reﬂecting the extra white
Europeanpatientsalreadytreatedwithlaser
photocoagulation. Excluding patients who
had previously undergone photocoagula-
tionfromtheSTRcategorywouldresultina
signiﬁcant excess risk of STR for the South
Asian patients.
Duration of diabetes and glycemic
control are well-established risk factors
for retinopathy, conﬁrmed in the current
study ﬁndings (2). The signiﬁcant inter-
action of ethnicity and duration of diabe-
tesobservedcomplicatesinterpretationof
the ethnicity effect in this study. Differen-
tial risk of retinopathy between South
Asian and white European patients is
largely observed in those with diabetes
duration of 10 years. This ﬁnding has
not been reported previously and empha-
sizes the need for effective screening and
earlier diagnosis of diabetes among the
South Asian population and suggests that
the pathogenesis of diabetic retinopathy
inthisgroupmaybemoreaggressivethan
that in white Europeans. Hypertension
has been shown to be strongly associated
with diabetic retinopathy in previous tri-
als and was an important modiﬁable fac-
tor in the current study (2,15). As in
previous trials, no signiﬁcant association
of diabetic retinopathy and total choles-
terol was observed (15,16). There was a
strong association between retinopathy
and treatment with insulin. Tightening
glycemic control rapidly may precipitate
progressionofdiabeticretinopathy,andit
is possible that insulin therapy has con-
tributed to the progression of retinopathy
inthesepatients(17).Itseemsmorelikely
that insulin treatment is only initiated in
response to the identiﬁcation of compli-
cations; recent evidence conﬁrms
resistance to early conversion to insulin
therapy in this population (12).
The current study found a higher
prevalence of retinopathy than was ob-
servedintheUKPDS,reﬂectingthelonger
duration of diabetes and risk factors pro-
ﬁle (2,10). A large screening-based study
in Liverpool during the 1990s reported
27% retinopathy including 6% STR (18).
This result is signiﬁcantly lower than the
Coventry prevalence, possibly reﬂecting
a secular trend over time plus differences
in the ethnicity composition of the sam-
ples; the Liverpool study had no compar-
ison of ethnicity-deﬁned groups. In
Bradford patients aged 40 years attend-
ing a diabetic outpatient’s clinic, a 60%
prevalence of retinopathy was detected,
including 38% STR, with statistically sig-
niﬁcantly excess STR in the South Asian
group (8). The prevalence is signiﬁcantly
higherthanthatinCoventryandincludes
ethnicity comparisons, but these were
hospital clinic patients, who are unlikely
to be representative of the community
at large. Studies from the U.S. have re-
ported retinopathy prevalences of up to
40%, with signiﬁcant variation between
ethnicity-deﬁned groups (19,20). Taken
together, these studies illustrate the po-
tential effects of sample selection, lending
weight to the importance of using popu-
lation-based screening data in retinopa-
thy studies—with ethnicity recorded, as
in the current study.
In the U.K., ethnic minority popula-
tions including South Asians are concen-
trated mainly in identiﬁable urban areas,
reﬂecting historical migration patterns.
Areas such as Coventry and Birmingham
are appropriate for comparative studies,
and high recruitment (61%) and reten-
tion (90% after 1 year) rates were
achieved for the UKADS trial (12). The
current study included South Asian and
white European patients from the same
innercitypractices,sharingthesamehigh
deprivation scores. Previous hospital-
based studies were smaller, and samples
Table 2—Clinical data: potentially confounding risk factors by ethnicity
Risk factors comparison South Asian White European P (t test)
n 421 492
Attained age 60.6  11.2 67.5  11.6 0.0001
Duration of diabetes
(years)
7.6  7.3 8.8  5.7 0.0001
Age at diagnosis (years) 53.0  12.0 58.6  12.3 0.0001
Systolic blood pressure
(mmHg)
144.1  20.8 137.0  18.7 0.0001
Diastolic blood pressure
(mmHg)
84.2  11.5 74.3  10.3 0.0001
Total cholesterol
(mmol/l)
4.5  1.2 4.2  1.1 0.0001
A1C (%) 7.9  1.6 7.5  1.6 0.0001
Plasma creatinine
(mol/l)
101.5  26.8 114.5  38.9 0.0001
Data are means  SD. No. of individuals with missing data: 1, attained age; 19, duration of diabetes; 13,
systolic blood pressure; 22, diastolic blood pressure; 13, total cholesterol; 11, A1C; and 13, plasma creatinine.
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economic status bias or other biases re-
lated to secondary care referral or access.
As with any study involving informed
consent, we cannot entirely exclude the
possibilityofselectionbias,butbyusinga
community-based screening program
with a high proportion of patients re-
cruited and retained, this was minimized.
One limitation may be generalization of
ﬁndings to nonurban populations be-
cause cultural factors may have an impact
ondiabetes,itsmanagement,patientcon-
cordance, and development of diabetic
retinopathy. One strength of this study
was the use of high-resolution digital
photographs graded according to stan-
dard national quality-assurance proto-
cols, although this grading is not as
detailed as and uses less grades than the
gradingsystemsusedinpreviousresearch
(15).
Large-scale studies of South Asians in
India have reported prevalences of dia-
betic retinopathy lower than those ob-
served in white European populations;
one study reported a prevalence of
17.6%, with increasing risk for men, ele-
vated A1C levels, older age, treatment
with insulin, and longer duration of dia-
betes (9). The prevalence reported was
much lower compared with the current
and previous estimates for U.K.-resident
South Asian patients (8). Although most
risk factors appear similar, it is of interest
that systolic blood pressure in the
younger South Asians in India was not a
signiﬁcant predictor of retinopathy and
that mean blood pressures were much
lower than those in the current study (9).
Studies in India have shown differential
rural and urban population lifestyle pro-
ﬁlesassociatedwithdifferentialriskfactor
proﬁles, particularly increasing insulin
resistance and hyperglycemia; these ob-
servations may help explain higher rates
of diabetes and diabetes complications,
including retinopathy, reported in South
Asians in the U.K. (21).
Across the world, wide variations in
retinopathy prevalences have been re-
ported, identifying ethnic groups such as
Maoris and Paciﬁc Islanders and African,
Mexican,andHispanicAmericansashav-
ing a particularly high risk (22,23). Dif-
ferential risk may be explained by
different levels of the potentially modiﬁ-
able risk factors hyperglycemia and
hypertension,withvaryingdiabetesdura-
tion possibly reﬂecting earlier disease on-
set in these population groups. Whereas
genetic differences between racial groups
might contribute, such a contribution is
relatively small compared with that of the
modiﬁable risk factors (8,9,24). System-
atic screening for retinopathy combined
with intensive management of diabetes,
including reduction of blood glucose and
blood pressure to international targets,
could help to reduce the incidence of vi-
sual impairment and blindness in ethnic
minority groups across the world, ad-
dressing an important health inequality.
Health care professionals in devel-
opedanddevelopingcountriesneedtobe
aware of the potential contribution of di-
abetic retinopathy to visual loss in South
Asiancommunities.High-qualitydataare
needed to monitor retinopathy incidence
as well as prevalence and to investigate
the effectiveness of interventions to mod-
ify known risk factors through aggressive
treatment of blood pressure and glyce-
mia. Screening for diabetic retinopathy is
Figure1—Retinopathystage,meanA1C(1SEM),andmeansystolicbloodpressure(1SEM)
by ethnicity. A: South Asian, n  413; white European, n  475. B: South Asian, n  414; white
European, n  478.  , South Asian; f, white European.
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and across the developed world, but cov-
erage rates and uptake among ethnic mi-
nority groups in inner city areas may be
much lower than those for white Europe-
ans (4). An awareness that these patients
havethehighestriskofvisualimpairment
orblindnessthroughacombinationofin-
adequatescreening,earlyonsetofdisease,
and poorly controlled risk factors, partic-
ularly glycemia and blood pressure, is the
ﬁrst step toward development of pro-
gramstorectifytheseimportanthealthin-
equalities (7,12).
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